Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma

Hematology Journal

Volumn 5, Issue 2, 2004, Pages 118-122

  Ria, Roberto ^a   Falzetti, Franca ^b   Ballanti, Stelvio ^b   Minelli, Olivia ^c   Di Ianni, Mauro ^b   Cimminiello, Michele ^b   Vacca, Angelo ^a   Dammacco, Franco ^a   Martelli, Massimo F ^b   Tabilio, Antonio ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Hospital of Perugia   (Italy)

Author keywords

Autologous stem cell transplantation; Conditioning regimen; High dose chemotherapy; Multiple myeloma; Survival

Indexed keywords

BUSULFAN; INTERFERON; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GRAM NEGATIVE INFECTION; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; PYREXIA IDIOPATHICA; STAPHYLOCOCCUS INFECTION; STATISTICAL ANALYSIS; STEM CELL MOBILIZATION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; FEMALE; GRAFT SURVIVAL; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 11144358209     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200369     Document Type: Article

References (46)

1. Harousseau J-L. Management of multiple myeloma. Rev Clin Exp Hematol 2002; 6: 253-275.
2. Salmon SE, Cassidy RJ. Plasma cell neoplasias in cancer. In: de Vita Jr VT, Hellman S, Rosenberg SA (eds). Principles and Practices of Oncology, 3rd edn. J. B. Lippincott Co., Philadelphia, USA, 1989: pp. 1862-1895.
3. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484-489.
4. Goldschmidt H, Egerer G, Ho AD. Autologous and allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2000; 25: S25-S26.
5. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
6. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
7. Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077-3085.
8. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
9. Palumbo A, Pileri A, Triolo S, Omede P, Bruno B, Ciravegna G et al. Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. Bone Marrow Transplant 1997; 19: 23-29.
10. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
11. Byrne JL, Carter GI, Bienz N, Haynes AP, Russell NH. Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma. Bone Marrow Transplant 1998; 22: 639-643.
12. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495-502.
13. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
14. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666-1672.
15. Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Fournie B et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79: 1130-1136.
16. Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J et al. Long-term followup after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998; 21: 1101-1107.
17. Alegre A, Lamana M, Arranz R, Fernandez-Villalta MJ, Tomas JF, Figuera A et al. Busulphan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 1995; 91: 380-386.
18. Bensinger WI, Rowley SD, Demirer T, Lilleby K, Schiffman K, Clift RA et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447-1456.
19. Mansi J, Da Costa F, Viner C, Judson I, Gore M, Cunningham D. High-dose busulphan in patients with myeloma. J Clin Oncol 1992; 10: 1569-1573.
20. Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood 1994; 8: 4278-4282.
21. Ventura GJ, Barlogie B, Hester JP, Yau JC, LeMaistre CF, Wallerstein RO et al. High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma. Bone Marrow Transplant 1990; 5: 265-268.
22. Adkins DR, Salzman D, Boldt D, Kuhn J, Irvin R, Roodman GD et al. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. J Clin Oncol 1994; 12: 1890-1901.
23. Mehta J, Tricot G, Jagannath S, Desikan KR, Siegel D, Singhal S et al. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplant 1997; 20: 113-116.
24. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200mg/m(2) melphalan and 8 Gy total body irradiation plus 140mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002; 99: 731-735.
25. Durie BGM. Staging and kinetics of multiple myeloma. Semin Oncol 1986; 13: 300-309.
26. Greipp P. Advances in the diagnosis and management of myeloma. Semin Hematol 1992; 29: 24-45.
27. Blade J, Samson D, Reece D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
28. Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 1-7.
29. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; ii: 822-824.
30. Gore ME, Selby PJ, Viner C, Clark PI, Meldrum M, Millar B et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; ii: 879-882.
31. Cunningham D, Paz-Ares L, Gore ME, Malpas J, Hickish T, Nicolson M et al. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol 1994; 12: 764-778.
32. Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica 2000; 85: 52-58.
33. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-763.
34. San Miguel JF, Blade J, Garcýa-Sanz R. Treatment of multiple myeloma. Haematologica 1999; 84: 36-58.
35. Schiller G, Nimer S, Vescio R, Lieb G, Lee M, Gajewski J et al. Phase I-II study of Busulphan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma. Bone Marrow Transplant 1994; 14: 131-136.
36. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Brandt L, Alegre A et al. Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells 1995; 13: S140S146.
37. Bensinger WI. Allogeneic hematopoietic cell transplantation for multiple myeloma. Biomed Pharmacother 2002; 56: 133-138.
38. Dimopoulos MA, Alexainan R, Przepiorka D, Hester J, Andersson B, Giralt S et al. Thiotepa, busulphan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324-2328.
39. Meloni G, Capria S, Trasarti S, Ferrazza G, Micozzi A, Petrucci MT et al. High-dose idarubicine, busulphan and melphalan as conditioning for autologous stem cell transplantation in multiple myeloma. A feasibility study. Bone Marrow Transplant 2000; 26: 1045-1049.
40. Barlogie B, Jagannath S, Nauche S, Mattox S, Bracy D, Crowley J et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998; 21: 1101-1107.
41. Lahuerta JJ, Martinez-Lopez J, Grande C, Bladè J, de la Serna J, Alegre A et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 2000; 109: 138-147.
42. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
43. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
44. Reece DE, Brockington DA, Phillips GL, Barnett MJ, Klingemann HG, Nantel SH et al. Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma. Bone Marrow Transplant 2000; 26: 621-626.
45. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 1995; 15: 165-171.
46. Lahuerta JJ, Grande C, Blade J, Martinez-Lopez J, De L, Alegre A et al. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma. Leuk Lymph 2002; 43: 67-74.